BriaCell Therapeutics (CVE:BCT) Trading Down 3.8%

Shares of BriaCell Therapeutics Corp. (CVE:BCT) traded down 3.8% during trading on Friday . The company traded as low as C$10.60 and last traded at C$10.60. 3,402 shares were traded during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.

The business’s 50 day moving average price is C$11.61 and its 200 day moving average price is C$9.33. The stock has a market capitalization of C$168.68 million and a P/E ratio of -28.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68.

BriaCell Therapeutics (CVE:BCT) last announced its quarterly earnings results on Tuesday, December 14th. The company reported C($0.19) EPS for the quarter.

About BriaCell Therapeutics (CVE:BCT)

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.

Read More: Special Dividends

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.